HELIX BIOPHARMA CORP overview

VANCOUVER, BC / ACCESSWIRE / April 22, 2022 / Mr. Jerzy Wilczewski announces the acquisition of 7,700,000 common shares (" Common Shares ") in the capital of Helix Biopharma Corp. (" Helix " or the " Company ") (TSX: HBP ) at a price of $0.26 per Common Share by way of non-brokered private placement for an aggregate subscription price of C$2,002,000 (the " Private Placement "). As a result of the closing of the Private Placement, Mr. Wilczewski beneficially owns, or exercises control or...

RICHMOND HILL, ON / ACCESSWIRE / April 21, 2022 / Helix BioPharma Corp. (TSX:HBP) ("Helix" or the "Company"), a clinical-stage biopharmaceutical company developing unique therapies in the field of immuno-oncology, based on its proprietary technological platform DOS47, today announces that it has closed a private placement financing for net proceeds of $2,002,000 from the issuance of 7,700,000 common shares at a price of $0.26 per common share. Mr. Jerzy Wilczewski ("Mr. Wilczewski"), an insider...

RICHMOND HILL, ON / ACCESSWIRE / April 18, 2022 / Helix BioPharma Corp. (TSX:HBP) ("Helix" or the "Company"), a clinical-stage biopharmaceutical company developing unique therapies in the field of immuno-oncology, based on its proprietary technological platformDOS47, is pleased to announce that Artur Gabor has been appointed as the Company's Chief Executive Officer with immediate effect. The Company is also pleased to announce the addition of three new members to its Board of Directors (the...

RICHMOND, ON / ACCESSWIRE / April 13, 2022 / Helix BioPharma Corp. (TSX:HBP) ("Helix" or the "Company"), a clinical-stage biopharmaceutical company developing unique therapies in the field of immuno-oncology, based on its proprietary technological platform DOS47, is pleased to announce that it has received conditional approval from the Toronto Stock Exchange (the "TSX") to extend its previously announced Early Warrant Exercise Incentive Program (the "Incentive Program") from April 28, 2022 to...

RICHMOND HILL, ON / ACCESSWIRE / April 7, 2022 / Helix BioPharma Corp. (TSX:HBP) ("Helix" or the "Company"), a clinical-stage biopharmaceutical company developing unique therapies in the field of immuno-oncology, based on its proprietary technological platform DOS47, today announced the resignation of Dr. Krzysztof Saczek from the Board of Directors with immediate effect. "On behalf of Helix, I would like to thank Krzysztof for his service to the Company" said Mr. Artur Gabor, Chair of the Audit...

RICHMOND HILL, ON / ACCESSWIRE / March 22, 2022 / Helix BioPharma Corp. (TSX:HBP) ("Helix" or the "Company"), a clinical-stage biopharmaceutical company developing unique therapies in the field of immuno-oncology, based on its proprietary technological platform DOS47, today announced that Frank Michalargias has notified the Board of Directors of the Company of his intention to resign from the position of Chief Financial Officer, effective no later than May 15, 2022. Mr. Michalargias will be...

RICHMOND, ON / ACCESSWIRE / March 16, 2022 / Helix BioPharma Corp. (TSX:HBP), (" Helix " or the " Company "), a clinical-stage biopharmaceutical company developing unique therapies in the field of immuno-oncology based on its proprietary technological platform DOS47, today announced fiscal 2022 second quarter results for the period ending January 31, 2022. OVERVIEW The Company reported a net loss and total comprehensive loss of $2,019,000 and 3,832,000 for the three and six-month periods ended...

RICHMOND HILL, ON / ACCESSWIRE / March 16, 2022 / Helix BioPharma Corp. (TSX:HBP) ("Helix" or the "Company") today announces, with great sadness, the sudden passing of its Interim Chief Executive Officer and Chairman of the Board of Directors (the "Board"), Prof. Dr. S Slawomir Majewski. Dr. Majewski has been on the Board since 2012 and has led the Company as its Interim Chief Executive since September 2021. He had been Head of the Department of Dermatology and Venereology, Warsaw Medical...